Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Bridgewater, New Jersey 08807


The primary objective is to determine the maximum tolerated dose of AVE9633 and to characterize the dose limiting toxicity(ies). Secondary objectives are to determine the anti-leukemia activity, the global safety and the PK profile.


Inclusion Criteria: - Patients with CD33-positive acute myeloid leukemia, refractory or relapsed after standard treatment with no curative option available - ECOG performance status 0 to 2 Exclusion Criteria: - Therapy with gemtuzumab ozogamicin (Mylotarg) within 6 months prior to inclusion - Allogenic transplantation within 6 months prior to inclusion - Prior therapy (chemotherapy, targeted agents, radiotherapy) within 3 weeks except for hydroxyurea and for leukophoresis - Previous treatment with AVE9633 - Poor kidney, liver and bone marrow functions - Any serious active disease or co-morbid condition, which in the opinion of the principle investigator, will interfere with the safety or with compliance with the study - Pregnant or breast-feeding women - Patient with reproductive potential without effective birth control methods The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study is Available At:

Original ID:




Secondary ID:

EudraCT 2006-005976-41

Study Acronym:

Brief Title:

Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia

Official Title:

An Open Label, Dose-Escalation Safety and Pharmacokinetic Study of AVE9633 Administered as a Single Agent by Intravenous Infusion on Day 1, Day 4 and Day 7 of a 4-Week Cycle in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML

Overall Status:


Study Phase:

Phase 1



Minimum Age:

18 Years

Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:


Oversight Authority:

  • United States: Food and Drug Administration
  • France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
  • Spain: Spanish Agency of Medicines

Reasons Why Stopped:

due to absence of evidence of clinical activ

Study Type:


Study Design:

Allocation: Non-Randomized, Endpoint Classificati

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:ICD CSD
Study Director

Study Dates

Start Date:September 2007
Completion Date:August 2008
Completion Type:Actual
Primary Completion Date:August 2008
Primary Completion Type:Actual
Verification Date:May 2009
Last Changed Date:May 13, 2009
First Received Date:October 12, 2007

Study Outcomes

Outcome Type:Secondary Outcome
Measure:Incidence of Adverse Events
Time Frame:Study period
Safety Issues:True
Outcome Type:Secondary Outcome
Measure:Complete Remission (CR) / Remission with incomplete platelet recovery (CRp), Partial Remission (PR) rate, time to CR and duration of CR, peripheral blast clearance
Time Frame:Study period
Safety Issues:False
Outcome Type:Primary Outcome
Measure:Incidence of Dose Limiting Toxicity(ies) at each tested dose level
Time Frame:Study period
Safety Issues:True

Study Interventions

Intervention Type:Drug
Description:Intravenous Infusion

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Sanofi-Aventis

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.